Engineered immune cells take on lupus kidney disease in early trial

NCT ID NCT06935474

Terminated Disease control Sponsor: AbelZeta Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-phase study tests a new treatment called C-CAR168 for people with lupus nephritis that hasn't improved with standard therapies. C-CAR168 is made from a patient's own immune cells, which are modified to target and attack faulty immune cells. The study will enroll 24 adults and focus on safety, tolerability, and finding the right dose. Participants will receive a single infusion after a short course of chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C-CAR168 (a CAR T-cell therapy targeting CD20 and BCMA proteins)
What this could lead to: If successful, this could point toward a new treatment option for people with lupus nephritis that hasn't responded to standard therapies.
What could go wrong: This is a very early, small study (24 people) focused on safety and dosing. It may not show clear benefit, and CAR T-cell therapy carries risks like severe immune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS (LN)

Contacts and locations

Locations

AbelZeta, Inc.

Rockville, Maryland, 20850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.